IMMUNOGLOBULIN G1-KAPPA AURISTATIN F CONJUGATE, ANTI-(HOMOSAPIENS CD19 (B LYMPHOCYTE SURFACE ANTIGEN B4, LEU-12)), HUMANIZED MONOCLONAL ANTIBODY

Follicular Lymphoma, Grade 3b

Seagen Inc.antibody_drug_conjugatePhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

210 Active assets in the Follicular Lymphoma, Grade 3b cohort.

Asset / Sponsor	Phase	Rating
CYCLOSPORIN A Fred Hutchinson Cancer Center	Phase 2/3	BBB
Romidepsin City of Hope Medical Center	Phase 2	BBB
VINCRISTINE SULFATE National Cancer Institute (NCI)	Phase 3	BBB
Irinotecan University of Michigan Rogel Cancer Center	Phase 2	BBB
Busulphan Masonic Cancer Center, University of Minnesota	Phase 2/3	BBB

View all 50 →

Same molecule, other indications

IMMUNOGLOBULIN G1-KAPPA AURISTATIN F CONJUGATE, ANTI-(HOMOSAPIENS CD19 (B LYMPHOCYTE SURFACE ANTIGEN B4, LEU-12)), HUMANIZED MONOCLONAL ANTIBODY is also rated in:

diffuse large B-cell lymphomaDormant

CCC

Indicative ·

53 / 100

View asset →

B-cell non-Hodgkin lymphomaDormant

CCC

Indicative ·

51 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →